STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:
Important clinical data published in 2011 and significant upcoming news-flow Cash burn in line with guidance and €139.5 million in cash at end 2011
Transgene (Paris:TNG)(Euronext Paris: FR0005175080) announces today its annual financial results for 2011 and updates the market on its strategy and its portfolio of product candidates. The consolidated 2011 financial statements were approved by the Board of Directors on March 15, 2012, and will be submitted for approval by the shareholders of the Company during its next annual general meeting, on June 21, 2012. The audit procedures have been performed and the auditors’ report will be issued upon review of the annual report.
